| Literature DB >> 26821179 |
Kristina Elfving1,2, Deler Shakely3,4, Maria Andersson1, Kimberly Baltzell5, Abdullah S Ali6, Marc Bachelard2, Kerstin I Falk7, Annika Ljung1, Mwinyi I Msellem6, Rahila S Omar6, Philippe Parola8, Weiping Xu3, Max Petzold9, Birger Trollfors2, Anders Björkman3, Magnus Lindh1, Andreas Mårtensson3,10,11.
Abstract
BACKGROUND: Despite the fact that a large proportion of children with fever in Africa present at primary health care facilities, few studies have been designed to specifically study the causes of uncomplicated childhood febrile illness at this level of care, especially in areas like Zanzibar that has recently undergone a dramatic change from high to low malaria transmission.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26821179 PMCID: PMC4731140 DOI: 10.1371/journal.pone.0146054
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart from investigations and management to final diagnoses.
Fig 2Baseline specimen collection and investigations.
Study definitions.
| Definition | Explanation |
|---|---|
| Fast breathing | >50 breaths/min for patients aged 2–11 months; >40 breaths/min for patients aged 12–59 months |
| Fever | Verified fever or fever by history in the preceding 24 hours |
| Verified fever | ≥37.5°C, axillary temperature |
| Severe disease | Symptoms/signs according to the IMCI guidelines |
| Abnormal laboratory values | CRP >200 mg/L; WBC >35*10^9/L; PLC <20*10^9/L; Hb<6 g/dL |
| Infections Requiring Antibiotics (InfRA) | Infection expected to benefit from systemic antibiotics, defined by the study team in retrospect |
| IMCI indicating antibiotic treatment (IMCIAB) | Classification in IMCI that indicates systemic antibiotics |
| IMCI pneumonia | Cough and/or difficult breathing and fast breathing |
| Serious bacterial infection | CXR-confirmed pneumonia and/or urinary tract infection |
| Discontinued due to withdrawal of consent | Withdrawal of consent by the care taker for participation in the study |
| Discontinued due to severe disease or severe laboratory values | Patient developed severe disease or severe laboratory values within the 14-day follow-up period |
| Death | The patient died within the 14-day follow-up period |
| Incomplete follow up data | No data on first or second scheduled follow-up. |
| Lost to follow up | Patient did not return for the final 14 day scheduled follow-up visit and could not be traced |
| Completed | Patient completed all follow-ups and did not fulfil any of the above-mentioned outcomes. |
| Follow-up 1 | Patient follow-up on day 4 (+/-2 days). Primarily based on IMCI |
| Follow-up 2 | Patient follow-up on day 14 (+/-2 days). Study outcome follow-up |
| Early resolution of fever | No verified fever on follow-up 1 and 2 |
| Late resolution of fever | Verified fever on follow-up 1. No verified fever on follow-up 2 |
| Relapse | No fever on follow-up 1. Verified fever on follow-up 2 |
| No resolution of fever | Verified fever on follow-up 1 and 2 |
a Patients not meeting these criteria but with a CRP of >150 mg/L, WBC >25*10^9/L, or PLC<50*10^9/L were followed up the next day.
ARI, Acute respiratory tract infection
CRP, C-reactive protein
CXR, Chest X-ray
GE, gastroenteritis
Hb, haemoglobin
IMCI, Integrated Management of Childhood Illnesses Guidelines
InfRA, Infections requiring systemic antibiotic treatment
PLC, platelet counts
RDT, Rapid Diagnostic Test
WBC, White blood cell counts.
Fig 3Flow of patients through the study.
Diagnostic criteria and study interventions.
| Final diagnosis | Criteria in clinical history or examination | Investigation criteria | InfRA | Intervention |
|---|---|---|---|---|
| Acute ear infection | Reported ear discharge≤14 days | no | Yes | No |
| Chronic ear infection | Reported ear discharge>14 days | no | Yes | No |
| Malaria | no | Malaria RDT or microscopy or PCR + | NO | Yes |
| Measles | no | Morbilli PCR + | No | No |
| Whooping cough | Common cold | Pertussis PCR: Ct<35 | Yes | No |
| CXR-confirmed pneumonia | Fast breathing | Chest X-ray shows end-point consolidation | Yes | Yes |
| Streptococcal skin infection (scarlet fever or impetigo) | Scarlatine skin rash or impetigo | RDT GAS+ | Yes | Yes |
| Streptococcal tonsillitis | Sore throat/tonsillitis/lymphadenitis | RDT GAS+ | Yes | Yes |
| Urinary tract infection | No diarrhoea | Positive urine culture | Yes | Yes |
| Pyelonephritis | No diarrhoea | Same criteria as Urinary tract infection AND CRP≥50. | Yes | Yes |
| Dysentery | History of bloody stools | PCR+ | If | No |
| GE diagnoses | ≥3 loose stools per day | PCR+ | If | No |
| ARI diagnoses | no | PCR+ | If | No |
| Possible streptococcal infection | no | RDT GAS+ | Yes | Yes |
| GE diagnoses | ≥3 loose stools per day | PCR+ | If | No |
| ARI diagnoses | no | PCR+ | No | No |
| No defined aetiology | Not fulfilling any group 1 or group 2 diagnoses | no | No | Yes |
a In cases of positive malaria microscopy, undetected by RDT, these patients were to be treated with antimalarials.
b WHO defined radiology criteria for diagnosis of pneumonia (Cherian et al, 2005)
c If suspected severe disease on CXR, patients were referred to a paediatric specialist
d All RDT GAS positive were treated with Penicillin V if not already treated with an equivalent antibiotic
e Significant growth of urinary pathogens on urine culture, ≥10^4 cfu/ml.
f Patients with positive urine cultures were treated with an antibiotic corresponding to the susceptibility pattern
g Rectal swab PCR.
h More likely cause of disease pathogens: Norovirus GII, rotavirus, Cryptosporidium with Ct<35, enterotoxigenic E. coli (heat stable toxin) with Ct<31, and Shigella spp with Ct<30.
i Less likely cause of disease pathogens Adenovirus, Campylobacter and sapovirus, Cryptosporidium with Ct≥35, enterotoxigenic E. Coli (heat lable toxin), enterotoxigenic E. coli (heat stable toxin) with Ct≥31, Shigella with Ct≥30
j Nasopharyngeal swab PCR
k More probable cause of disease pathogens: Enterovirus, influenza A virus, influenza B virus, RSV
m Less probable cause of disease pathogens: Adenovirus, bocavirus, Chlamydophila pneumoniae, coronavirus, metapneumovirus, parainfluenza virus, parechovirus and rhinovirus.
For all nasopharyngeal and rectal swab PCRs: Ct-values<40 were disregarded in the final analysis.
Factors associated with CXR-confirmed pneumonia among patients with IMCI pneumonia.
| CXR-confirmed pneumonia | No CXR-confirmed pneumonia | Unadjusted OR (CI) | Adjusted OR (CI) | |||
|---|---|---|---|---|---|---|
| (n = 42) | (n = 300) | |||||
| Mean age, months (SD) / OR (CI) | 20.2 (1.97) | 16.4 (0.63) | 1.03 (1.00–1.05) | 0.041 | 1.03 (1.0–1.1) | 0.051 |
| Mean CRP, mg/L (CI) / OR (CI) | 61.5 (9.9) | 26.0 (1.7) | 1.02 (1.01–1.02) | <0.0001 | 1.02 (1.01–1.03) | <0.0001 |
| Mean WBC, 109/L / OR (CI) | 14.5 (1.1) | 12.3 (0.2) | 1.08 (1.0–1.2) | 0.009 | 1.02 (0.9–1.1) | 0.6 |
| Child perceived as having fast breathing by care taker | 85% (73–96%) | 75% (70–80%) | 1.8 (0.7–4.5) | 0.2 | 1.9 (0.7–5.2) | 0.19 |
| Temperature ≥39.0°C (CI) | 11% (7–15%) | 14% (4–25%) | 1.3 (0.5–3.5) | 0.53 | 1.2 (0.4–4.0) | 0.31 |
| CRP | 36% (21–50%) | 62% (56–67%) | 0.3 (0.2–0.7) | 0.002 | ||
| CRP | 24% (11–37%) | 5% (3–7%) | 5.9 (2.4–14.3) | <0.0001 | ||
| WBC >20 x 109/L (CI) | 10% (6–18%) | 6% (3–9%) | 1.6 (0.5–5.1) | 0.4 | ||
| Pneumococcal urine antigen positivity (CI) | 59% (43–74%) | 58% (53–64%) | 1.0 (0.5–1.9) | 0.99 | 1.3 (0.6–2.9) | 0.48 |
| Pneumococcal NPH PCR positivity (CI) | 88% (78–98%) | 86% (82–90%) | 1.2 (0.4–3.2) | 0.75 | ||
| RSV NPH PCR positivity (CI) | 26% (13–40%) | 35% (30–40%) | 0.7 (0.3–1.4) | 0.26 | 0.7 (0.3–1.6) | 0.36 |
| IfA or IfB NPH PCR positivity (CI) | 14% (4–25%) | 18% (14–23%) | 0.7 (0.3–1.8) | 0.52 | 0.6 (0.2–1.8) | 0.38 |
28 of 387 patients with IMCI pneumonia had no CXR performed. Another 17 patients were excluded from analysis because CXR was of too poor quality (n = 16) or missing (n = 1) CXR.
aCXR-confirmed pneumonia was seen in 8% (15/200) of patients with CRP <20 mg/L (p = 0.002), and in 40% (10/25) of those with CRP >80 mg/L (p<0.0001).
bNot included in final multivariate regression analysis
Demographic, socioeconomic and clinical characteristics of study participants.
| Characteristics | Patients | Healthy controls |
|---|---|---|
| Number of enrolled participants | 677 (100%) | 167 (100%) |
| Male | 352 (52%) | 86 (51%) |
| Female | 325 (48%) | 81 (49%) |
| Median age months (IQR) | 14 (9–24) | 24 (12–36) |
| 2–11 months | 232 (34%) | 32 (19%) |
| 12–23 months | 231 (34%) | 42 (25%) |
| 24–35 months | 109 (16%) | 41 (25%) |
| 36–59 months | 105 (16%) | 52 (31%) |
| Median reported fever duration; days (IQR); (range) | 3 (2–4) | |
| No school education | 253 (37%) | |
| ≤6 years education | 92 (14%) | |
| >6 years education | 317 (47%) | |
| Breastfeeding children <24 months | 434 (94%) | |
| Fully immunized | 420 (94%) | |
| Antibiotics consumed before study inclusion | 56 (8%) | |
| Paracetamol consumed before study inclusion | 375 (55%) | |
| Underweight; % below -2SD (CI) | 28.3 (24.9–31.8) | |
| Median temperature (IQR) | 37.3 (36.8–38.0) | |
| 36.0–37.4 | 375 (55%) | |
| 37.5–39.0 | 240 (35%) | |
| >39.0 | 46 (7%) | |
| Fever | 644 (95%) | |
| Cough | 580 (86%) | |
| Runny nose | 455 (67%) | |
| Diarrhoea | 158 (23%) | |
| Abdominal pain | 35 (5%) | |
| Vomiting | 34 (5%) | |
| Ear pain | 21 (3%) | |
| Loss of appetite | 17 (3%) | |
| 500 (74%) | ||
| One type of antibiotic | 394 (79%) | |
| Two types of antibiotics | 103 (21%) | |
| Three types of antibiotics. | 3 (0.1%) | |
| Beta lactam antibiotics / parenteral benzyl penicillin | 470 (93%) / 112 (17%) | |
| Trimethoprim/sulfamethoxazole | 74 (11%) | |
| Other types of antibiotics | 95 (14%) |
Denominators vary due to missing data (n≤10 if not indicated)
IQR = Interquartile range
aMissing data n>10, ≤50
bDenominator patients<24 months: n = 463
c BCG, OPV3, Pentavalent/DPT3, measles
dDenominator patients>11 months: n = 445.
Fig 4IMCI classifications associated with fever.
Fig 5ABC. Pathogen detection in samples collected on enrolment day.
Fig 6Final diagnoses in patients.
Fig 7A: Proportions of patients with an antibiotic indication by IMCI (IMCIAB) and actual antibiotic prescription (AB) in patients with and without infections requiring antibiotics (InfRA/no InfRA). B: Final diagnoses in patients with Infections Requiring Antibiotics (InfRA). C: Final diagnoses in patients without Infections Requiring Antibiotics (non-InfRA).